DOCTORS'
Medical Case Studies
DOCTORS'
Medical Case Studies
Lucentis intravitreal injections
Ranibizumab
Ranibizumab (trade name Lucentis) is a monoclonal antibody fragment derived from the same parent mouse antibody as bevacizumab (Avastin). It is much smaller than the parent molecule and has been affinity matured to provide stronger binding to VEGF-A. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (ARMD), a common form of age-related vision loss. Some investigators believe that bevacizumab at an average cost of $42 a dose (in the U.S. ) is as effective as ranibizumab at an average cost of $1,593 a dose...
Lucentis intravitreal injections - List of case studies
- Age Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
-
as having Polypoidal Choroidal Vasculopathy and he had an intravitreal injection of Avastin. Following this, the patient had a Vitrectomy ... in the left eye. A treatment option would be additional Lucentis or Avastin intravitreal injections, and the patient should consider ...
- Myopic Maculopathy
-
to date, however, he is a good candidate for Lucentis or Avastin intravitreal injections into the right eye in attempt to halt the ...
- Drugs
-
Avastin Avastin (bevacizumab) Avastin intravitreal injections Avonex Avonex (interferon beta 1a) ... heparins Low-molecular-weight-heparin Lucen Lucentis Luteal support Lyrica Lyrica (75 mg) M ...